These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 20350628)

  • 21. Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models.
    van Schaijk FG; Oosterwijk E; Molkenboer-Kuenen JD; Soede AC; McBride BJ; Goldenberg DM; Oyen WJ; Corstens FH; Boerman OC
    J Nucl Med; 2005 Mar; 46(3):495-501. PubMed ID: 15750164
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Radioimmunotherapy of solid tumors: the promise of pretargeting strategies using bispecific antibodies and radiolabeled haptens.
    Reilly RM
    J Nucl Med; 2006 Feb; 47(2):196-9. PubMed ID: 16455623
    [No Abstract]   [Full Text] [Related]  

  • 23. A universal pretargeting system for cancer detection and therapy using bispecific antibody.
    Sharkey RM; McBride WJ; Karacay H; Chang K; Griffiths GL; Hansen HJ; Goldenberg DM
    Cancer Res; 2003 Jan; 63(2):354-63. PubMed ID: 12543788
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial.
    Kraeber-Bodéré F; Rousseau C; Bodet-Milin C; Ferrer L; Faivre-Chauvet A; Campion L; Vuillez JP; Devillers A; Chang CH; Goldenberg DM; Chatal JF; Barbet J
    J Nucl Med; 2006 Feb; 47(2):247-55. PubMed ID: 16455630
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metastatic human colonic carcinoma: molecular imaging with pretargeted SPECT and PET in a mouse model.
    Sharkey RM; Karacay H; Vallabhajosula S; McBride WJ; Rossi EA; Chang CH; Goldsmith SJ; Goldenberg DM
    Radiology; 2008 Feb; 246(2):497-507. PubMed ID: 18227543
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel bispecific, trivalent antibody construct for targeting pancreatic carcinoma.
    Gold DV; Goldenberg DM; Karacay H; Rossi EA; Chang CH; Cardillo TM; McBride WJ; Sharkey RM
    Cancer Res; 2008 Jun; 68(12):4819-26. PubMed ID: 18559529
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic advantage of pretargeted radioimmunotherapy using a recombinant bispecific antibody in a human colon cancer xenograft.
    Karacay H; Brard PY; Sharkey RM; Chang CH; Rossi EA; McBride WJ; Ragland DR; Horak ID; Goldenberg DM
    Clin Cancer Res; 2005 Nov; 11(21):7879-85. PubMed ID: 16278412
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cancer radioimmunotherapy.
    Sharkey RM; Goldenberg DM
    Immunotherapy; 2011 Mar; 3(3):349-70. PubMed ID: 21395378
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods.
    Sharkey RM; Karacay H; Cardillo TM; Chang CH; McBride WJ; Rossi EA; Horak ID; Goldenberg DM
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7109s-7121s. PubMed ID: 16203810
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Delivery of therapeutic doses of radioiodine using bispecific antibody-targeted bivalent haptens.
    Gautherot E; Le Doussal JM; Bouhou J; Manetti C; Martin M; Rouvier E; Barbet J
    J Nucl Med; 1998 Nov; 39(11):1937-43. PubMed ID: 9829586
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel radiolabeled antibody conjugates.
    Goldenberg DM; Sharkey RM
    Oncogene; 2007 May; 26(25):3734-44. PubMed ID: 17530026
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Perspectives on cancer therapy with radiolabeled monoclonal antibodies.
    Sharkey RM; Goldenberg DM
    J Nucl Med; 2005 Jan; 46 Suppl 1():115S-27S. PubMed ID: 15653660
    [TBL] [Abstract][Full Text] [Related]  

  • 33. α- Versus β-Emitting Radionuclides for Pretargeted Radioimmunotherapy of Carcinoembryonic Antigen-Expressing Human Colon Cancer Xenografts.
    Heskamp S; Hernandez R; Molkenboer-Kuenen JDM; Essler M; Bruchertseifer F; Morgenstern A; Steenbergen EJ; Cai W; Seidl C; McBride WJ; Goldenberg DM; Boerman OC
    J Nucl Med; 2017 Jun; 58(6):926-933. PubMed ID: 28232604
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma.
    Sharkey RM; Karacay H; Johnson CR; Litwin S; Rossi EA; McBride WJ; Chang CH; Goldenberg DM
    J Nucl Med; 2009 Mar; 50(3):444-53. PubMed ID: 19223402
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bespoke Pretargeted Nanoradioimmunotherapy for the Treatment of Non-Hodgkin Lymphoma.
    Au KM; Tripathy A; Lin CP; Wagner K; Hong S; Wang AZ; Park SI
    ACS Nano; 2018 Feb; 12(2):1544-1563. PubMed ID: 29361211
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pretargeted radioimmunotherapy with a single-chain antibody/streptavidin construct and radiolabeled DOTA-biotin: strategies for reduction of the renal dose.
    Förster GJ; Santos EB; Smith-Jones PM; Zanzonico P; Larson SM
    J Nucl Med; 2006 Jan; 47(1):140-9. PubMed ID: 16391198
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diabody Pretargeting with Click Chemistry In Vivo.
    van Duijnhoven SM; Rossin R; van den Bosch SM; Wheatcroft MP; Hudson PJ; Robillard MS
    J Nucl Med; 2015 Sep; 56(9):1422-8. PubMed ID: 26159589
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pretargeted radioimmunotherapy.
    Meredith RF; Buchsbaum DJ
    Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S57-9. PubMed ID: 16979441
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor pretargeting for radioimmunodetection and radioimmunotherapy.
    Zhu H; Jain RK; Baxter LT
    J Nucl Med; 1998 Jan; 39(1):65-76. PubMed ID: 9443740
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immuno-PET Using Anticarcinoembryonic Antigen Bispecific Antibody and 68Ga-Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-in-Human Trial.
    Bodet-Milin C; Faivre-Chauvet A; Carlier T; Rauscher A; Bourgeois M; Cerato E; Rohmer V; Couturier O; Drui D; Goldenberg DM; Sharkey RM; Barbet J; Kraeber-Bodere F
    J Nucl Med; 2016 Oct; 57(10):1505-1511. PubMed ID: 27230928
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.